Fulvestrant

• CAT Number: A000986
• CAS Number: 129453-61-8
• Molecular Formula: C₂₃H₄₇F₅O₃S
• Molecular Weight: 606.77
• Purity: ≥95%
• Synonyms: 129453-61-8; Faslodex; ICI 182,780; Ici 182780; ICI-182780
• Target: Estrogen/progestogen Receptor
• Solubility: >30.3mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
• InChI: InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• InChIKey: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• SMILES: CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F

Fulvestrant（Cat No.:A000986）is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. It works by binding to estrogen receptors and promoting their degradation, thereby inhibiting estrogen signaling that promotes cancer cell growth. Fulvestrant is administered as an intramuscular injection and is often used in patients who have progressed on other endocrine therapies. Its unique mechanism of action makes it a critical option for advanced breast cancer management, providing an effective treatment for patients with resistant or recurrent disease.